Chengzhi Co., Ltd. (SHE:000990)
China
· Delayed Price · Currency is CNY 12.94
-0.23 (-1.75%)
Apr 29, 2026, 3:04 PM CST
Chengzhi Revenue
Chengzhi had revenue of 2.84B CNY in the quarter ending March 31, 2026, a decrease of -5.41%. This brings the company's revenue in the last twelve months to 10.87B, down -4.21% year-over-year. In the year 2025, Chengzhi had annual revenue of 11.03B, down -0.35%.
Revenue (ttm)
10.87B
Revenue Growth
-4.21%
P/S Ratio
1.45
Revenue / Employee
2.53M
Employees
4,295
Market Cap
15.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.03B | -38.43M | -0.35% |
| Dec 31, 2024 | 11.07B | -1.35B | -10.88% |
| Dec 31, 2023 | 12.42B | 700.11M | 5.98% |
| Jan 1, 2023 | 11.72B | -466.63M | -3.83% |
| Jan 1, 2022 | 12.18B | 2.45B | 25.20% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Jan 1, 2019 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jinyu Bio-technology | 1.33B |
| Anhui Anke Biotechnology (Group) | 2.56B |
| Inner Mongolia Furui Medical Science | 1.60B |
| Mabwell (Shanghai) Bioscience | 662.52M |
| InventisBio | 37.29M |
| Staidson (Beijing) BioPharmaceuticals | 220.23M |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |